{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:50:28Z","timestamp":1768319428094,"version":"3.49.0"},"reference-count":0,"publisher":"Wiley","issue":"4S3","license":[{"start":{"date-parts":[[2014,11,2]],"date-time":"2014-11-02T00:00:00Z","timestamp":1414886400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of the International AIDS Society"],"published-print":{"date-parts":[[2014,11]]},"abstract":"Introduction<\/jats:title>According to recent evidence about boosted protease inhibitors (PIs\/r)\u2010simplified regimens, the combination of 3TC and DRV\/r 800\/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment\u2010experienced HIV+ patients.<\/jats:p><\/jats:sec>Patients and Methods<\/jats:title>We retrospectively evaluated patients switching to 3TC+DRV\/r, with at least six months of viral suppression, no resistance mutation to DRV or 3TC and not HBV\u2010coinfected: incidence of ART discontinuation and of virological failure (VF: 2 consecutive HIV\u2010RNA determinations>49 cps\/mL or a single one\u22651000 cps\/mL) and the probability of remaining discontinuation\u2010free during one\u2010year follow\u2010up (FU), as well as changes in laboratory parameters at 1, 3, 6 and 12 months were estimated.<\/jats:p><\/jats:sec>Results<\/jats:title>We included 94 patients: 74 males, mostly MSM (39.4%), with 49 years old, 9 years of HIV disease, 8 years of ART (median values). Median nadir CD4 count and zenith viral load (log10) were 194 cells\/\u00b5L and 4.90, respectively. Ten patients were HCV\u2010coinfected and 38 had at least a previous VF. Seventy\u2010four patients were on an NRTIs\u2010based triple regimen (mainly TDF\/FTC or 3TC\/ABC) whereas 14 on another PI\u2010based dual therapy (mainly LPV\/r). Incidence of treatment discontinuation was 12.4 per 100 patients\u2010year follow\u2010up (PYFU), but only 2 patients experienced a VF (3.5 per 100 PYFU). Mean time free from discontinuation was 5 years (95% CI 4\u20136), with a cumulative one\u2010year estimated probability of staying on 3TC+DRV\/r of 85.9%. At three months, a trend of increased CD4 cells count (+42 cells\/\u00b5L, p 0.059) was observed, but not confirmed at later time point; an increase of total cholesterol (TC, +17mg\/dL, p 0.008) and LDL (+19 mg\/dL, p 0.002), and a decreased level of AST and ALT (\u22122 UI\/L, p 0.045; \u22125 UI\/L, p 0.009, respectively) were also detected. Total bilirubin was reduced (\u22120.71 mg\/dL, p 0.038). At 6 and 12 months, alteration of lipid profile was similar, with also an increased TC\/HDL ratio (+0.48, p=0.030, at six months) and HDL\/LDL ratio (\u22120.04, p=0.035, at 12 months). A significant decrease in ALT levels (\u22126 UI\/L, 0.013) and a diminishing trend for AST and total bilirubin, as well as a significant increase in renal function (GFR +4mL\/min, p 0.048) were observed at 12 months.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>These observations on 3TC+DRV\/r\u2010based dual therapy simplification in virologically suppressed patients show a good profile of efficacy and safety. An extended FU time is needed in order to establish the real impact of this promising therapeutic choice.<\/jats:p><\/jats:sec>","DOI":"10.7448\/ias.17.4.19817","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T08:30:34Z","timestamp":1415003434000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Switching to lamivudine plus darunavir\/r dual therapy in a cohort of treatment\u2010experienced HIV\u2010positive patients: the experience of an Italian centre"],"prefix":"10.1002","volume":"17","author":[{"given":"Alberto","family":"Borghetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Mondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Piccoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Lamonica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"D'Avino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pallavicini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Cauda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Fabbiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,2]]},"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.7448%2FIAS.17.4.19817","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.7448\/IAS.17.4.19817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:15:19Z","timestamp":1695575719000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.7448\/IAS.17.4.19817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":0,"journal-issue":{"issue":"4S3","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.7448\/IAS.17.4.19817"],"URL":"https:\/\/doi.org\/10.7448\/ias.17.4.19817","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"2014-11-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"19817"}}